RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma
Results from the real-world US PATRIOT-II study.
Grivas, P., Barata, P. C., Moon, H. H., Gupta, S., Hutson, T. E., Sternberg, C. N., Brown, J., Dave, V., Downey, C., Shillington, A. C., Katzenstein, H., Kirker, M., Hanson, S., Liu, F. X., Morris, V. A., Bhanegaonkar, A., & Sonpavde, G. P. (2024). Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.Journal of Clinical Oncology, 42(4_SUPPL), 697-697. https://doi.org/10.1200/JCO.2024.42.4_suppl.697